Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study

BMC Gastroenterology

Ad AM Masclee¹  Joanna W Kruimel¹  Gwen M Masclee¹  Gwen H Dackus¹  Daniel Keszthelyi¹ 

[1] Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands

关键词: Intestinal permeability;    Small intestinal bacterial overgrowth;    NSAIDs;    Proton pump inhibitors;    Irritable bowel syndrome;   

Others  :  1088673
DOI  :  10.1186/1471-230X-12-121

 received in 2012-04-03, accepted in 2012-08-30,  发布年份 2012

【 摘 要 】

Background

Patients with irritable bowel syndrome (IBS) seen by a gastroenterologist often utilize medications that may alter intestinal homeostasis. The question arises whether exposure to these drugs is associated with the development of IBS symptoms. Aim of this study was therefore to assess the use of PPIs and NSAIDs in patients with IBS versus controls.

Methods

Cases of IBS from the last 5 years were reviewed. All patients having had at least one prescription for a particular drug (PPIs, NSAIDs, SSRIs, diuretics, ACE inhibitors) in the 6 months prior to the time of initial symptom onset were considered exposed. The control group consisted of individuals randomly selected from the general population.

Results

287 cases of IBS were retrieved for analysis together with 287 age and sex-matched controls. Exposure to PPIs and NSAIDs was significantly higher in IBS patients, whereas no association between ACE inhibitor use and IBS was found. PPIs were not significantly associated when excluding patients with gastrointestinal reflux disease or functional dyspepsia. Exposure to SSRIs was also positively associated with IBS, but only when patients with psychiatric comorbidity were included in the analyses.

Conclusions

Medications that may alter intestinal homeostasis such as NSAIDs and PPIs were more frequently used in IBS patients compared to controls. This association might be relevant for everyday clinical practice, but it is remains to be elucidated whether this association is of etiological nature.

【 授权许可】

   
2012 Keszthelyi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Drossman DA, Camilleri M, Mayer EA, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123(6):2108-2131.
• [2]Akehurst RL, Brazier JE, Mathers N, O'Keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ: Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002, 20(7):455-462.
• [3]Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, Hietbrink F, Bartelink IH, Busschers WB, Samsom M, Renooij W: Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci 2010, 55(3):716-723.
• [4]Spiegel BM, Chey WD, Chang L: Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008, 103(12):2972-2976.
• [5]Stichting Farmaceutische Kerngetallen (SKF): Facts and figures 2009. 2010. Available from: http://www.sfk.nl/pdf-documenten/data-en-feiten/data-en-feiten-2009 webcite, accessed 15 August
• [6]Forgacs I, Loganayagam A: Overprescribing proton pump inhibitors. BMJ 2008, 336(7634):2-3.
• [7]van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD: Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther 2009, 29(5):571-579.
• [8]Goettsch WG, van den Boom G, Breekveldt-Postma NS, Smout AJ, Herings RM: Treatment patterns and health care costs of mebeverine-treated IBS patients: a case–control study. Pharmacoepidemiol Drug Saf 2004, 13(11):803-810.
• [9]Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA: Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case–control study. Aliment Pharmacol Ther 2010, 32(9):1124-1128.
• [10]Limsui D, Pardi DS, Camilleri M, Loftus EV Jr, Kammer PP, Tremaine WJ, Sandborn WJ: Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007, 13(2):175-181.
• [11]Burgel N, Bojarski C, Mankertz J, Zeitz M, Fromm M, Schulzke JD: Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002, 123(2):433-443.
• [12]Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, Tully O, Kearney K, Lazowick D, Mercogliano G, et al.: Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008, 28(11–12):1317-1325.
• [13]Lombardo L, Foti M, Ruggia O, Chiecchio A: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010, 8(6):504-508.
• [14]Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC: Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 2011, 141(5):769-776.
• [15]Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD: Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003, 98(11):2454-2459.
• [16]Ford AC, Marwaha A, Lim A, Moayyedi P: Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010, 8(5):401-409.
• [17]Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ: Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol 2000, 95(1):157-165.
• [18]Talley NJ, Zinsmeister AR, Melton LJ 3rd: Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995, 142(1):76-83.
• [19]Bjarnason I, MacPherson A, Hollander D: Intestinal permeability: an overview. Gastroenterology 1995, 108(5):1566-1581.
• [20]Kalantar JS, Locke GR 3rd, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ 3rd: Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points. Aliment Pharmacol Ther 2003, 17(11):1389-1397.
• [21]Bjarnason I, Hayllar J, MacPherson AJ, Russell AS: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104(6):1832-1847.
• [22]Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128(5):1172-1178.
• [23]Fujimori S, Gudis K, Takahashi Y, Seo T, Yamada Y, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, et al.: Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest 2010, 40(6):504-510.
• [24]Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, et al.: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011, 141(4):1314-1322. 1322 e1311-1315
• [25]Lewis SJ, Franco S, Young G, O'Keefe SJ: Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996, 10(4):557-561.
• [26]Williams C, McColl KE: Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006, 23(1):3-10.
• [27]Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, et al.: Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996, 39(1):54-59.
• [28]Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, Blum A, Bille J, Gonvers JJ, Gyr K: Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994, 35(1):23-26.
• [29]Spiegel BM: Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011, 9(6):461-469. quiz e459
• [30]Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR 3rd, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA: Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011, 33(9):1059-1067.
• [31]Keszthelyi D, Masclee AA: Effects of proton pump inhibitor therapy in the distal gut: putting the pieces together. Dig Dis SciEpub 17 Aug 2012